Filtered By:
Source: Neurology
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 3153 results found since Jan 2013.
Late treatment with choline alfoscerate increases hippocampal neurogenesis and provides protection against seizure-induced neuronal death and cognitive impairment (P1.229)
Conclusions:The present study suggests that application of α-GPC after seizure may serve as a beneficial treatment for improvement of cognitive function in epilepsy patientsDisclosure: Dr. Yoo has nothing to disclose. Dr. Shin has nothing to disclose. Dr. Lee has nothing to disclose. Dr. SONG has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Yoo, J., Shin, D. J., Lee, B., SONG, H. Tags: Epilepsy and Clinical Neurophysiology: Basic Science Source Type: research
Increased Epilepsy Prevalence in Adults with 22q11 Deletion Syndrome (P1.236)
Conclusions:The prevalence of provoked seizures in adults with 22q11.2DS is higher than in the general population. Hypocalcemia continues to be risk factor for adults, but differently from children, adults with 22qDS are more exposed to psychotropic medications and are more vulnerable to seizures caused by them compared to the general population. These patients are also more likely to develop genetic generalized and focal epilepsy, structural epilepsy (due to malformation of cortical development, trauma, stroke). Further prospective studies are warranted to investigate how 22q11.2 microdeletion leads to an overall decrease...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Wither, R., MacDonald, A., Borlot, F., Butcher, N., Chow, E., Bassett, A., Andrade, D. Tags: Epilepsy and Clinical Neurophysiology: Genetics Source Type: research
Misdiagnosis of CADASIL: A single Medical Center experience (P1.251)
Conclusions:CADASIL is the most prevalent monogenic cerebral small-vessel arteriopathy. Despite wide availability of genetic testing, misdiagnosis and delay diagnosis are common. We encourage for enhanced awareness of CADASIL among patients with migraines with aura, recurrent TIAs or subcortical ischemic strokes, and mood disorder, in order to provide appropriate multidisciplinary treatment, psychological support and genetic counselingStudy Supported by: n/aDisclosure: Dr. Ortiz-Garcia has nothing to disclose. Dr. Orjuela has nothing to disclose. Dr. Sweis has nothing to disclose. Dr. Biller has received personal compensat...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Ortiz-Garcia, J., Orjuela, K., Sweis, R., Biller, J. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research
Is fabrys disease a risk factor for stroke in young patients? (p1.252)
Conclusions:Although as much as 40% of young patients with ischemic stroke have no clear etiology, extensive investigation for possibly treatable causes is warranted and should include Fabry’s Disease.Disclosure: Dr. Ikuta has nothing to disclose. Dr. Scavasine has nothing to disclose. Dr. Canever has nothing to disclose. Dr. Zamproni has nothing to disclose. Dr. Lange has nothing to disclose. Dr. Germiniani has nothing to disclose. Dr. Zetola has nothing to disclose. Dr. Werneck has nothing to disclose. Dr. Novak has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Ikuta, C., Scavasine, V., Canever, M., Zamproni, L., Lange, M., Germiniani, F., Zetola, V., Werneck, L., Novak, E. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research
A rare cause of stroke in young: PHACE syndrome (P1.253)
Conclusions:Neurocutaneous syndromes are typically diagnosed in childhood and can be a rare cause of stroke in young. Our patient suffered an ischemic stroke secondary to sequelae of undiagnosed PHACE syndrome. Early identification of neurocutaneous syndromes allows for proper surveillance, evaluation, and preventative education for development of complications.Disclosure: Dr. Fitzgerald has nothing to disclose. Dr. Chandra has nothing to disclose. Dr. Dannenbaum has nothing to disclose. Dr. Sharrief has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Fitzgerald, K., Chandra, S., Dannenbaum, M., Sharrief, A. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research
Deficiency of adenosine deaminase 2: a recently described autoinflammatory disease with neurological manifestations (p1.254)
Conclusions:DAD2 involves a spectrum of neurological symptoms and MRI findings. Mutations at amino acids 154–204 of the CECR1 gene are more likely to cause neurological symptoms than mutations elsewhere in CECR1. A better understanding of these neurological manifestations will aid in earlier diagnosis, which can reduce morbidity, mortality, and unnecessary testing.Disclosure: Dr. Noll has nothing to disclose. Dr. Kessler has nothing to disclose. Dr. Gratton has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Noll, A., Kessler, E., Gratton, S. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research
MELAS Syndrome: How Stroke-like are the Stroke episodes? (P1.255)
Conclusions:Patients with MELAS syndrome may present with recurrent strokes in the arterial territory rather than SLEs. Clinicians should entertain the possibility of a mitochondrial disease in young patients with cryptogenic stroke and pursue appropriate diagnostic evaluations and treatment.Disclosure: Dr. Liaw has nothing to disclose. Dr. Lewis has nothing to disclose. Dr. Saini has nothing to disclose. Dr. Gultekin has nothing to disclose. Dr. Koch has nothing to disclose. Dr. Asdaghi has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Liaw, N., Lewis, R., Saini, V., Gultekin, S. H., Koch, S., Asdaghi, N. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research
THE SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs) IN CYTOCHROME P450 2C19 AND CLOPIDOGREL RESISTANCE IN INDIAN POPULATION (P1.256)
Conclusions:There is high prevalence of CYP2C19*2 allele in Indian population resulting in clopidogrel resistance/treatment failure.Disclosure: Dr. Shivaraman M M has nothing to disclose. Dr. Nazarene has nothing to disclose. Dr. Ranganathan has nothing to disclose. Dr. Ravi Chandar has nothing to disclose. Dr. S has nothing to disclose. Dr. Shankar has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Shivaraman, M. A., Nazarene, A., Ranganathan, L. N., Chandar, C. S. R., Kumar, S. P., Shankar, G. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research
Circulating Microparticles are Associated with Visuospatial Ability in the Framingham Heart Study (P1.257)
Conclusions:An association was observed between circulating levels of platelet MPs and reduced performance on the Hooper Visual Organization Test, a measure sensitive to cerebrovascular disease. The results are hypothesis-generating and further research is needed to understand the potential role of MPs in cognitive dysfunction.Study Supported by:NHLBI (N01-HC-25195; HHSN268201500001I), NINDS (R01NS017950), NIA (T32-AG036697) and AHA (15GPSPG23770000).Disclosure: Dr. Aparicio has nothing to disclose. Dr. Himali has nothing to disclose. Dr. Pase has nothing to disclose. Dr. Satizabal has nothing to disclose. Dr. Plourde-Davi...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Aparicio, H. J., Himali, J., Pase, M., Satizabal, C., Plourde-Davis, K., Boulanger, C., Amabile, N., Cheng, S., Larson, M., DeCarli, C., Vasan, R., Wang, T., Beiser, A., Seshadri, S. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research
D-Lactate and Intestinal Fatty-Acid Binding Protein are elevated in serum in patients with acute ischemic stroke (P1.258)
Conclusions:D-Lactate and IFABP were significantly elevated in patients with AIS, but concentrations were not associated with stroke severity. This provides, for the first time, indirect evidence of disruption of the intestinal barrier in patients with AIS.Disclosure: Dr. Camara-Lemarroy has nothing to disclose. Dr. Escobedo-Zúñiga has nothing to disclose. Dr. Guzman-De la Garza has nothing to disclose. Dr. Castro-Garza has nothing to disclose. Dr. Vargas-Villarreal has nothing to disclose. Dr. Góngora-Rivera has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Camara-Lemarroy, C., Escobedo-Zuniga, N., la Garza, F. G.-D., Castro-Garza, J., Vargas-Villarreal, J., Gongora-Rivera, F. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research
Relationship between admission serum bilirubin and severity of acute ischaemic stroke in a nigerian tertiary hospital (p1.259)
Conclusion:Patients with higher physiologic range of serum bilirubin had more severe stroke (higher NIHSS values), suggesting that higher bilirubin values at stroke onset might be a reflection of oxidative intensity.Disclosure: Dr. Ademiluyi has nothing to disclose. Dr. Sanya has nothing to disclose. Dr. Wahab has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Ademiluyi, B., Sanya, E., Wahab, K. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research
Interleukin-37 is Elevated in Acute Ischemic Stroke (P1.260)
Conclusions:The study shows a rather stable elevation of IL-37 levels post-ischemic stroke, which if compared to available data from other studies, is 3–10 times elevated after acute ischemic stroke with an uptrend in the first few days. IL-37 plays some role in mediating post-stroke inflammation with significant rise in serum and urine IL- 37 levels suggesting a key role of this novel cytokine in post-stroke pathology.Disclosure: Dr. Bushnaq has nothing to disclose. Dr. Zafar has nothing to disclose. Dr. Duraisamy has nothing to disclose. Dr. Tasneem has nothing to disclose. Dr. Khan has nothing to disclose. Dr. Lei...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Bushnaq, S., Zafar, A., Duraisamy, K., Tasneem, N., Khan, M., Leira, E., Zaheer, A. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research
Increased Cysteinylated Albumin is Associated with More Favorable Outcomes in Ischemic Stroke Patients, A Reflection of Collateral Circulation? (P1.261)
Conclusions:Increasing levels of cysteinylated albumin were associated with more favorable discharge mRS and less mortality. Cysteinylated (oxidized) albumin may reflect the presence of collateral circulation in equilibrium with the peripheral circulation from where venous blood samples were obtained for this study.Disclosure: Dr. Bartt has nothing to disclose. Dr. Leonard has nothing to disclose. Dr. Bar-Or has nothing to disclose. Dr. Rael has nothing to disclose. Dr. Bar-Or has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Bartt, R., Leonard, J., Bar-Or, R., Rael, L., Bar-Or, D. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research
The relationship between chemerin levels and carotid intima-media thickness in patients with ischemic stroke (P1.262)
Conclusions:Consequently, this study showed that serum chemerin levels may play role in atherosclerosis and ischemic stroke.Study Supported by: Fırat University (FÜBAP)Disclosure: Dr. Demir has nothing to disclose. Dr. Atas has nothing to disclose. Dr. Aytaç has nothing to disclose. Dr. Gonen has nothing to disclose. Dr. Erten has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Demir, C., Ataş, I., Aytac, E., Gonen, M., Erten, Z. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research
Purinoreceptors and VZV Vasculopathy (P1.263)
Conclusions:Overall, VZV infection caused a transient rise in extracellular ATP. Importantly, we found that aside from its known antiplatelet effects, P2Y12 antagonist clopidogrel also inhibits VZV infection, independent of downstream inhibition of glycoprotein IIB/IIIA, and may serve as an alternative antiviral therapy for VZV vasculopathy.Disclosure: Dr. Wyborny has nothing to disclose. Dr. Choe has nothing to disclose. Dr. Totaro has received personal compensation for activities with Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, and Teva as a speaker. Dr. Gerasimovskaya has nothing to discl...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Wyborny, A., Choe, A., Traktinskiy, I., Gerasimovskaya, E., Gilden, D., Nagel, M. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research
